Juneyao Health released an investor relations record, stating that the main change in its business this year is the gradual transition of its subsidiary, Juneyao Biogrowing, into the core platform for probiotics. While “WeiDongLi” still plays a role in maintaining the stability of the company’s core business, the majority of incremental growth comes from Biogrowing and probiotic end products. Biogrowing has achieved excellent capacity utilization in the first half of the year, with a capacity utilization rate exceeding 120% in May. Currently, the company’s order expectations have far exceeded its production capacity. (Source: baijiahao)
Sign Up to Receive China Updates Weekly Newsletter for FREE, CLICK HERE
Visit HPA-China’s Information Hub, CLICK HERE